MintNeuro has signed a partnership with Motif Neurotech to advance the development of miniature BCI therapy for mental health conditions.

Dexcom is maintaining its prior FY26 outlook in view of the current geopolitical realities such as higher oil prices due to Iran’s closure of the Strait of Hormuz in response to the US-Israel’s war ...

The funds will advance Axoft’s existing clinical trial programmes and progress US regulatory activities for its implantable brain-computer interface.

GE HealthCare has cut its 2026 growth outlook by 3.3% at the top end, citing increasing freight costs for oil and other materials.

Neuromodulation is an adjunct to medication for Parkinson’s symptom management, with growing interest in whether it could one day contribute to disease-modifying therapies.

Swiss biotech AC Immune discusses its PET tracer's potential in realising precision medicine approaches to neurodegenerative diseases.

Should the transaction complete, J&J will inherit Atraverse’s radiofrequency system for simplifying access to the heart’s left atrium.

The MUSC and Revival Healthcare Capital have entered a partnership aimed at advancing the clinical development of medical technologies.

The FDA has awarded a breakthrough device designation for Capitan Orthopedics' SupraSpacer implant for patients with irreparable rotator cuff tears.

VVeno Medical has received the IDE approval from the US FDA for a pivotal study involving a non-surgical replacement venous valve.

Adagio Medical has reported positive six-month data from its FULCRUM-VT trial, supporting its plans to seek FDA premarket approval for the vCLAS system.

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large medtech companies.